The First FDA Approved Muscle Growth Drug Is Here! Here’s the Catch.

Summary

The video discusses myostatin inhibitors—drugs intended to increase muscle growth by blocking myostatin, a protein that normally limits muscle development. The presenter describes animal examples and rare human cases associated with little or no functional myostatin. They suggest that inhibiting myostatin could help preserve muscle during weight loss and address age-related or disease-related muscle loss.

Claims that these drugs could produce bodybuilder-level growth with few side effects are presented as possibilities, not established outcomes for ordinary users.

Featured drug: apitegromab

Apitegromab is a monoclonal antibody developed by Scholar Rock. According to the video, clinical-trial results showed that over 24 weeks, people taking tirzepatide lost about 55% less muscle when apitegromab was added: approximately 1.5 kg, compared with 3.4 kg in the tirzepatide-only group. Participants were not lifting weights.

The video also reports improved muscle volume and physical function in people with serious muscle disorders.

Limitations

The main limitations are access and cost:

• Apitegromab is administered by hospital infusion, rather than as a convenient at-home injection or pill.
• It is a prescription treatment for medical conditions, not an accessible bodybuilding drug.
• The video estimates a course of treatment at about $350,000 per year, while predicting that prices may fall over time.
• The trial findings do not establish that recreational users can safely obtain dramatic muscle gains.

The video argues that more practical myostatin-blocking treatments—such as self-administered injections or oral drugs—would be needed before these medicines could see broad fitness use. Predictions that future drugs might replace steroids or transform bodybuilding are speculative.

Researchers and sources mentioned

• Scholar Rock — drug developer.
• Clinical trials — findings on apitegromab with tirzepatide and on muscle disorders; individual researchers and study citations are not named in the subtitles.
• FDA — referenced in connection with the drug’s approval.
• Examples cited — myostatin-deficient mice, greyhounds, cattle, and a rare human case. No specific studies or researchers are identified.